Pancreatic cancer is a grim diagnosis, with a five-year survival rate of less than 9 percent. To improve those odds, researchers at UPMC and the University of Pittsburgh School of Medicine sought genetic signatures in the largest study of its kind that could be used to better match drugs to patients and for early detection.
The study, published in the journal Gastroenterology, involved sifting through the genomes of thousands of tumors, sampled from all over the world. In 17 percent of cases, there was a genetic flag that indicated the tumor should be susceptible to existing chemotherapy drugs. The researchers also found supporting evidence for heritable genes, including some in the BRCA family associated with breast cancer that can predispose whole families toward pancreatic cancer.
“People have been looking for such markers for a long time, and our study shows that it’s possible to break pancreatic cancer patients into different treatment buckets,” said senior author and McGowan Institute for Regenerative Medicine affiliated faculty member Nathan Bahary, MD, PhD, oncologist at UPMC Hillman Cancer Center and associate professor of medicine at Pitt.
One reason why pancreatic cancer is so deadly is that the majority of patients often are identified late in their disease course and frequently present with inoperable tumors at the time of diagnosis. For some of these patients, it may be possible to shrink the tumor with existing chemotherapy drugs, but in a disease where 75 percent of patients die within a year of diagnosis, time is of the essence, and unfortunately, there’s no way to know in advance which patients will respond to which drugs.
“Every pancreatic cancer is different and performing molecular profiling of each patient’s tumor could help determine the best treatment options,” said lead author Aatur Singhi, MD, PhD, surgical pathologist at UPMC and assistant professor of pathology at Pitt. “Rather than blindly giving patients the same chemotherapy, we want to tailor a patient’s chemo to their tumor type. A one-size-fits-all approach isn’t going to work. Therefore, we would like to make molecular profiling standard-of-care for patients with pancreatic cancer.”
Drs. Singhi and Bahary’s study characterized the genome of 3,594 pancreatic tumor samples from patients around the world, provided by collaborators at Foundation Medicine.
“We believe that this is the largest study in pancreatic cancer conducted using comprehensive genomic profiling to identify a broad set of genomic alterations, and ultimately, therapeutic targets, in this difficult-to-treat disease,” said Siraj Ali, MD, PhD, senior director of clinical development at Foundation Medicine.
Besides shrinking tumors with personalized chemotherapy, another way to increase pancreatic cancer survival rates is through increased pancreatic cysts screening, Dr. Singhi said, but the problem is that pancreatic cysts are incredibly common, and not all lead to cancer.
Previously, Dr. Singhi and colleagues developed a clinical molecular test known as PancreaSeq to evaluate common pancreatic cysts and identify which cases may progress to cancer. Now Drs. Singhi and Bahary’s newly discovered biomarkers can be added to the PancreaSeq platform, already being used by several institutions, including UPMC.
Abstract (Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Aatur D. Singhi, MD PhD1, Ben George, MD2, Joel R. Greenbowe, PhD, Jon Chung, PhD, James Suh, MD, Anirban Maitra, MBBS, Samuel J. Klempner, MD, Andrew Hendifar, MD, Javle M. Milind, MD, Talia Golan, MD, Randall E. Brand, MD, Amer H. Zureikat, MD, Somak Roy, MD, Alexa B. Schrock, PhD, Vincent A. Miller, MD, Jeffrey S. Ross, MD, Siraj M. Ali, MD PhD, Nathan Bahary, MD, PhD. Gastroenterology, online 03/02/19.)